What's next in medical science—Precision, Prevention, and Prediction

As we stand at the cusp of an unprecedented era in medical science, the horizon is illuminated by a confluence of groundbreaking advances that collectively herald a profound transformation in healthcare.The trajectory of medicine today is distinguished not only by isolated discoveries but by the synergistic integration of diverse disciplines, such as omics, artificial intelligence, bioengineering, and data science, each amplifying the other's potential.This convergence is catalyzing innovations that promise to redefine our fundamental approach to understanding, preventing, diagnosing, and treating disease, moving beyond incremental improvements toward paradigmshifting revolutions. FROM REACTIVE TREATMENT TO PROACTIVE HEALTH MANAGEMENT Embracing proactive care for lasting wellnessA central theme emerging from this new era is the decisive transition from reactive to proactive medicine.For decades, healthcare systems have focused primarily on treating illness after its onset.However, the persistent global burden of chronic non-communicable diseases (NCDs), including cardiovascular and cerebrovascular diseases, cancer, chronic respiratory conditions, and metabolic diseases, demands a reorientation toward prediction, prevention, and sustained health maintenance (Figure 1). 1 The future of medicine lies in anticipating disease trajectories and intervening earlier, thereby mitigating or even averting the progression of illness.This philosophy is increasingly embraced by international health authorities such as the World Health Organization, which advocates for robust investment in primary prevention, health education, and accessible primary care infrastructure.These strategies yield far greater returns than late-stage disease management, both in terms of health outcomes and economic sustainability. Precision health: Customized prevention and therapyPrecision health epitomizes this transition.Large-scale initiatives, such as the PREDICT studies, have illuminated the remarkable heterogeneity in individual responses to diet, exercise, and environmental exposures.The era of one-size-fits-all health recommendations is giving way to personalized interventions informed by an individual's unique genomic, microbiomic, metabolomic, and behavioral profiles.The rapid clinical adoption of GLP-1 receptor agonists, 2 including Semaglutide and Tirzepatide, exemplifies this shift.These agents not only facilitate effective obesity management but also interrupt the cascade of obesity-related comorbidities, thereby fundamentally altering long-term health trajectories.